Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Claire Johnson

Nurse Practitioner Plano, TX Nurse Practitioner

NPI 1285324921 CMS profile 11502249

6617 Shadow Crest Dr, Plano, TX 75093

Open in the dashboard

General payments

$7,711

333 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Claire Johnson of Plano, TX is reported in the CMS Open Payments database as having received $7,711 across 333 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,902 120
2024 General $3,396 160
2023 General $1,413 53

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Claire Johnson
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Claire Johnson were reported at $2,902. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Claire Johnson Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $0 $152 $48–$470 $149
2023 $1,413 $166 $54–$529 $160
2024 $3,396 $173 $55–$556 $164
2025 $2,902 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AbbVie, Inc. $940 55 payments
  2. UCB, Inc. $876 28 payments
  3. ACADIA Pharmaceuticals Inc $421 15 payments
  4. Teva Pharmaceuticals USA, Inc. $336 20 payments
  5. Biogen, Inc. $306 13 payments
  6. Eisai Inc. $277 7 payments
  7. Pfizer Inc. $263 23 payments
  8. Lundbeck LLC $204 11 payments
  9. Lilly USA, LLC $204 10 payments
  10. Alexion Pharmaceuticals, Inc. $201 9 payments
  11. Other $3,685 142 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $7,634 332 payments
  2. Education $77 1 payment
Products named General payments · program years 2023–2025
  1. QULIPTA $493 31 payments
  2. UBRELVY $462 28 payments
  3. BOTOX $415 24 payments
  4. NUPLAZID $360 12 payments
  5. Briviact $342 12 payments
  6. Austedo XR $336 20 payments
  7. Rystiggo $281 9 payments
  8. Leqembi $277 7 payments
  9. NURTEC ODT $263 23 payments
  10. Gamunex-C $200 8 payments
  11. Other $5,195 223 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

333 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record